On November 9, 2015, the availability of a comprehensive new report “Non-Invasive Cancer Diagnostics Market, 2015-2030” was announced. Primarily driven by liquid biopsy, the report states, the non-invasive cancer diagnostics market is anticipated to grow aggressively at a healthy annual growth rate of 44% between 2015 and 2030. Prostate cancer, breast cancer, colorectal cancer, and lung cancer are likely to be the key indications which will drive the market; combined, these are expected to account for over 70% of the total liquid biopsy market in 2030. Cancer is an extremely complex disease and medical science is still struggling to figure out the factors influencing the disease origin, propagation, spread (metastasis), and relapse. In addition to satisfying the unmet market need for advanced and efficient treatment interventions, cancer prevention, early detection, and management are extremely important. The high cancer mortality rate is primarily due to delay in detection of the disease. Early diagnosis and screening makes it possible to cure the disease completely and/or increase survival rates. Over the years, various technological advances have helped medical professionals understand cancer better. Recent research in cancer biology has led to significant innovation in the development of a number of new diagnostic tools. These modern diagnostic techniques can help detect and classify cancer with increased accuracy and sensitivity. It is also important to highlight that the cost of management and treatment of cancer is a growing concern considering its generally highly progressive and often fatal nature.
Login Or Register To Read Full Story